Similarly, MSC-TRAIL combined with an AMPK inhibitor enhanced killing of glioblastoma cells by increasing expression of the pro-apoptotic BCL-2 family protein Bax and simultaneously reducing the expression of the anti-apoptotic proteins FLIP, XIAP and BCL-2 [204]. Here, BCL2 is linked to glioblastoma.